Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0000899243-20-004912)

Filing Details

Accession Number:: 0000899243-20-004912
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-02-18 17:02:19
Reporting Period:: 2020-02-14

Accepted Time:: 2020-02-18 17:02:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1346302	Xeris Pharmaceuticals Inc	XERS	Pharmaceutical Preparations (2834)	203352427

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1531178	R Paul Edick	C/O Xeris Pharmaceuticals, Inc. 180 N. Lasalle Street, Suite 1600 Chicago IL 60601	See Remarks	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-02-14	20,000	$4.15	183,134	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	13,430	Indirect	By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018

Footnotes

Represents shares purchased in an underwritten public offering of the Issuer at the public offering price of $4.15 per share.
The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.